USP22 and urinary bladder neoplasm: Notably treatment with USP22-specific siRNA and aiRNA (asymmetric interfering RNA) inhibits the growth of implanted bladder tumors in vivo [42], possibly through the downregulation of Mdm2 and cyclin E, resulting in the stabilization of p53 and p21 and ensuing cell cycle arrest [42].